First Trust Advisors LP Boosts Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

First Trust Advisors LP boosted its position in shares of Grifols, S.A. (NASDAQ:GRFSFree Report) by 6.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,684,749 shares of the biotechnology company’s stock after buying an additional 302,380 shares during the period. First Trust Advisors LP’s holdings in Grifols were worth $54,156,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of GRFS. Jump Financial LLC purchased a new stake in Grifols during the 3rd quarter worth approximately $136,000. QRG Capital Management Inc. acquired a new position in shares of Grifols during the 3rd quarter worth approximately $303,000. Black Creek Investment Management Inc. boosted its holdings in shares of Grifols by 16.4% during the 3rd quarter. Black Creek Investment Management Inc. now owns 9,574,388 shares of the biotechnology company’s stock worth $87,510,000 after purchasing an additional 1,351,000 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in shares of Grifols during the 3rd quarter worth approximately $419,000. Finally, Brandes Investment Partners LP boosted its holdings in shares of Grifols by 8.2% during the 3rd quarter. Brandes Investment Partners LP now owns 11,061,281 shares of the biotechnology company’s stock worth $101,100,000 after purchasing an additional 835,253 shares during the last quarter.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft cut Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th.

Get Our Latest Report on GRFS

Grifols Stock Down 3.6 %

Shares of Grifols stock opened at $7.24 on Friday. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15. The stock’s 50 day simple moving average is $6.95 and its 200-day simple moving average is $8.02. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.29 and a current ratio of 2.79.

About Grifols

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Read More

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFSFree Report).

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.